Internal Medicine, Pulmonary Disease · Tracy, CA
NPI
1871588731
Since 2005
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
530 W Eaton Ave, Suite E
Tracy, CA, 95376
Phone (209) 830-1500
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.1M
53,192 services
Medicare patients, 2024
1,075
Average age 74
Drug cost, 2024
$4.3M
5,129 prescriptions
Company payments, 2025
$301K
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Shyamsunder Subramanian was code J2356 (injection, tezepelumab-ekko, 1 mg), 17,220 times for 15 patients. In total Shyamsunder Subramanian billed 53,192 services in 41 codes, and Medicare paid $1.1M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-12-15.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2356 Injection, tezepelumab-ekko, 1 mg | Office | 17,220 | 15 | $10.21 | $176K |
| J2182 Injection, mepolizumab, 1 mg | Office | 15,400 | 19 | $20.28 | $312K |
| J0517 Injection, benralizumab, 1 mg | Office | 2,190 | 18 | $95.16 | $208K |
| 99214 Office E&M - Established | Office | 1,311 | 625 | $100.41 | $132K |
| 96372 Injection Administration | Office | 405 | 63 | $11.69 | $4,735 |
| J3590 Unclassified biologics | Office | 321 | 12 | $0.00 | $0.99 |
| 95806 Sleep Study | Office | 242 | 236 | $68.09 | $16K |
| 94729 Pulmonary Function Testing | Office | 233 | 230 | $7.16 | $1,669 |
| 94060 Pulmonary Function Testing | Office | 233 | 230 | $7.91 | $1,843 |
| 99213 Office E&M - Established | Office | 226 | 187 | $69.12 | $16K |
| 94726 Pulmonary Function Testing | Office | 226 | 223 | $9.39 | $2,122 |
| 99204 Office E&M - New | Office | 194 | 194 | $129.35 | $25K |
| 99215 Office E&M - Established | Office | 147 | 136 | $78.75 | $12K |
| 99233 Hospital E&M - Subsequent | Facility | 143 | 65 | $93.31 | $13K |
| 99291 Critical Care E&M | Facility | 61 | 30 | $165.57 | $10K |
By year: 2022 $903K for 26,893 services; 2023 $1.0M for 58,257 services; 2024 $1.1M for 53,192 services.
Medicare prescription drug claims, 2024
In 2024, the drug Shyamsunder Subramanian prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 830 prescriptions and refills. In total Shyamsunder Subramanian wrote 5,129 Medicare prescriptions that cost $4.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 830 | 1,167 | 206 | $717K |
| Montelukast Sodium Generic | 770 | 1,530 | 197 | $7,498 |
| Methylprednisolone Generic | 525 | 559 | 289 | $8,640 |
| Prednisone Generic | 253 | 274 | 112 | $1,302 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 237 | 301 | 102 | $179K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 215 | 231 | 93 | $6,685 |
| Roflumilast Generic | 185 | 216 | 33 | $14K |
| Azithromycin Generic | 167 | 169 | 116 | $1,151 |
| Dupixent Pen Dupilumab | 140 | 141 | 25 | $530K |
| Nucala Mepolizumab | 116 | 117 | 17 | $423K |
| Dupixent Syringe Dupilumab | 111 | 115 | 14 | $416K |
| Tezspire Tezepelumab-Ekko | 105 | 106 | 17 | $456K |
| Losartan Potassium Generic | 86 | 182 | 23 | $507 |
| Clonazepam Generic | 85 | 85 | 28 | $328 |
| Azelastine Hcl Generic | 80 | 131 | 41 | $1,695 |
Brand drugs: 2,200 claims; generic drugs: 2,929 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Shyamsunder Subramanian $301K ($301K in general payments such as food, travel and fees) from 19 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $88K.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 112 | $88K |
| Lilly USA, LLC LLY | 74 | $68K |
| Genzyme Corporation SNY | 36 | $66K |
| Regeneron Healthcare Solutions, Inc. REGN | 15 | $25K |
| GlaxoSmithKline, LLC. GSK | 28 | $20K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 17 | $18K |
| Verona Pharma, Inc. VRNA | 14 | $12K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 3 | $2,911 |
| Amgen Inc. AMGN | 19 | $295 |
| Jazz Pharmaceuticals Inc. JAZZ | 10 | $187 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.